Eton Pharmaceuticals (NASDAQ:ETON) Insider Ipek Erdogan-Trinkaus Sells 3,500 Shares of Company Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider Ipek Erdogan-Trinkaus sold 3,500 shares of Eton Pharmaceuticals stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $67.41, for a total value of $235,935.00. Following the completion of the transaction, the insider owned 4,081 shares of the company’s stock, valued at approximately $275,100.21. This trade represents a 46.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Eton Pharmaceuticals Stock Performance

NASDAQ:ETON opened at $61.45 on Friday. The business’s fifty day moving average is $55.18 and its 200 day moving average is $37.47. The firm has a market cap of $1.77 billion, a price-to-earnings ratio of 40.70 and a beta of 0.89. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.58 and a current ratio of 1.79. Eton Pharmaceuticals, Inc. has a 52-week low of $14.27 and a 52-week high of $70.64.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings results on Thursday, November 5th. The company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.19. The firm had revenue of $57.93 million for the quarter, compared to analysts’ expectations of $41.98 million. Eton Pharmaceuticals had a return on equity of 104.82% and a net margin of 35.35%. Research analysts predict that Eton Pharmaceuticals, Inc. will post 1.54 EPS for the current year.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Hilton Head Capital Partners LLC bought a new position in Eton Pharmaceuticals in the third quarter worth about $26,000. Global Retirement Partners LLC bought a new stake in Eton Pharmaceuticals during the 3rd quarter valued at approximately $26,000. Morse Asset Management Inc bought a new stake in Eton Pharmaceuticals during the 3rd quarter valued at approximately $35,000. Sterling Capital Management LLC grew its holdings in shares of Eton Pharmaceuticals by 845.7% during the 3rd quarter. Sterling Capital Management LLC now owns 889 shares of the company’s stock worth $46,000 after acquiring an additional 795 shares during the period. Finally, Toth Financial Advisory Corp purchased a new position in shares of Eton Pharmaceuticals during the 2nd quarter worth approximately $43,000. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on ETON shares. Canaccord Genuity Group raised their price target on Eton Pharmaceuticals from $68.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, November 6th. HC Wainwright upped their price target on shares of Eton Pharmaceuticals from $70.00 to $80.00 and gave the company a “buy” rating in a report on Friday, November 6th. Zacks Research downgraded shares of Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Craig Hallum reiterated a “buy” rating and set a $78.00 target price on shares of Eton Pharmaceuticals in a report on Thursday, October 15th. Finally, Weiss Ratings upgraded shares of Eton Pharmaceuticals from a “hold (c)” rating to a “buy (b-)” rating in a report on Monday. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Eton Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $79.75.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited treatment options. Its work includes bringing new medicines and reformulated or otherwise specialized drug products to market. The company’s products include Alkindi Sprinkle, a hydrocortisone granule formulation used to treat adrenal insufficiency, and Eprontia, an oral solution of topiramate used to treat certain seizure disorders and prevent migraines.